Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Pt. 1 Of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Dunsire takes stock of Millennium's business development mandate as part of a global organization, its clinical pipeline and other operational changes since the firm became the Takeda Oncology company.

You may also be interested in...



Back To School: Catch Up On Our Executive Interviews

Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.

Back To School: Catch Up On Our Executive Interviews

Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.

Standing Alone While Standing Together: A Conversation With Millennium CEO Dunsire (Pt. 2 Of 2)

Dunsire talks about what it takes for Millennium, Takeda's Oncology program, to operate a a stand-alone unit within the Japanese pharma, and strategies to retain key staff and culture.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel